

FOR IMMEDIATE RELEASE:

Contact:

Luanne Rodgers
Organ Recovery Systems
847-824-2600
lrodgers@organ-recovery.com

Chris Stamm or Tracy Paczkowski
Schwartz Communications, Inc.
781-684-0770
ors@schwartz-pr.com

**ORGAN RECOVERY SYSTEMS' ENHANCED KPS-1 KIDNEY PERFUSION
SOLUTION RECEIVES FDA CLEARANCE**

*Updates to Perfusion Solution Include Extended Six Month Shelf Life and Improved
Packaging Features*

CHICAGO, Ill.—October 28, 2002—Organ Recovery Systems, a developer of technologies and services to improve the quality and quantity of transplantable organs, tissues and cells, announced today that the United States Food & Drug Administration (FDA) has given the company clearance to market an improved version of its KPS-1™ Kidney Perfusion Solution. The recently cleared solution has an extended storage life of up to six months representing a marked improvement over the previous formula that remained viable for 120 days from the date of aseptic fill. In addition to an extended storage life, KPS-1 is now packaged in a system designed to provide greater product stability and meets the USP Class VI testing requirements. The new package includes an added injection port allowing aseptic delivery of pharmacological agents used in the perfusion of kidneys prior to transplant and a clear protective over-wrap bag which will allow the end user visualization of the solution prior to use.

The KPS-1 solution is an essential component of Organ Recovery Systems' kidney recovery system that uses proprietary machine perfusion techniques for organ evaluation and therapy. Hypothermic machine perfusion of organs—the process of passing chemical solutions through organs at cold temperatures to minimize tissue damage—has been shown to improve the condition of organs prior to transplant and to improve outcomes.

“In recent months, Organ Recovery Systems has made great strides in expanding the practice of perfusion to help improve the quality and number of organs available for transplantation,” said David Kravitz, CEO of Organ Recovery Systems. “Our company’s proprietary protocol, which includes the use of KPS-1 solution, has been used to treat thousands of kidneys for transplantation. This protocol has recently been employed in rescuing more than 600 kidneys that had previously been rejected for transplant. We look forward to continuing our support of machine perfusion by extending the shelf life of the KPS-1 solution and making it easier to handle.”

Of all the transplantable organs, kidneys are in greatest demand. While approximately 14,000 kidney transplants are performed each year in the United States, there are more than 52,000 prospective kidney transplant patients on organ waiting lists according to the United Network of Organ Sharing (UNOS). According to the U.S. Renal Data System, nearly 200,000 patients are being treated for end stage renal disease and depend on routine dialysis to stay alive. In addition, the U.S. Renal Data System projects that the current number of patients waiting for a kidney transplant will nearly double by 2010. Increasing the number of transplantable organs would provide many of these patients with the opportunity for a life-saving transplant and help limit the widening gap between patient demand and donor supply.

About Organ Recovery Systems

Organ Recovery Systems is a privately held company developing technologies and services to improve the quality and quantity of transplantable organs, tissues and cells. The company is comprised of three business units: the Perfusion Services Group that helps leading transplant centers and organ procurement organizations (OPO) by employing proprietary perfusion techniques for evaluation and therapy of traditional, expanded criteria and nonheartbeating donor kidneys prior to transplant; the Medical Devices Group that develops perfusion-based devices to improve the recovery, assessment, storage and transport of organs for transplantation; and the Charleston Research Center that develops new technology for cell and tissue preservation as well as basic and applied research to support the company's platform of organ therapy products. For more about Organ Recovery Systems visit <http://www.organ-recovery.com>.

###